Sold as Cibacalcin. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Calcitonin Human (sold as Cibacalcin), first approved Oct 31, 1986, with 0 new uses approved and 0 published complete response letters.
| Effects of a Preoperative Capsaicin-Containing Diet on Postoperative Liver Injury RepairPostoperative Liver Injury · Tongji Hospital | Not applicable | Not yet recruiting | Nov 9, 2026 |
| Psychological Support for Chronic Migraine Patients Treated With Anti-CGRP (Anti-Calcitonin Gene-Related Peptide ) Monoclonal AntibodiesChronic Migraine Headache, Psychologic Adaptation · Central Hospital, Nancy, France | — | Not yet recruiting | Oct 16, 2026 |
| A Phase 1 Study of VK3019 in Overweight and Obese Adults Without ComorbiditiesObese Adults · Viking Therapeutics, Inc. | Phase 1 | Recruiting | Sep 29, 2026 |
| Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With MigraineMigraine Disorders, Brain, Healthy Adult Participants · Konrad Peter Weber | Phase 4 | Not yet recruiting | Sep 17, 2026 |
| Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell CarcinomaOral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC) · Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Sep 10, 2026 |
| Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in MigraineChronic Migraine · Beni-Suef University | Not applicable | Recruiting | Aug 17, 2026 |
| Different Kinematics Within a Single-File System and Postoperative PainRoot Canal Treatment, Postoperative Pain · Jordan University of Science and Technology | Not applicable | Active, not recruiting | Jul 13, 2026 |
| Subcutaneous Calcitonin in Acute Herpes ZosterCalcitonin, Subcutaneous · Tanta University | Phase 3 | Recruiting | Jun 18, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Oct 31, 1986 | CibacalcinNDA 18470 · New molecular entity | Novartis | 4 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Novartis